Headline: AASLD Hot Updates on MASLD from the 2023 Annual Meeting

Headline: AASLD Hot Updates on MASLD from the 2023 Annual Meeting

2023.12.21
On November 7, 2023, at 12:30 PM local time in Boston, the American Association for the Study of Liver Diseases (AASLD) held its sole pre-conference press briefing on Metabolic Associated Fatty Liver Disease (MASLD). Chaired by conference president Professor Norah Terrault, the event featured presentations by Professor Phuc Le of the Cleveland Clinic Lerner College of Medicine, who discussed his team's model predicting the changing prevalence of liver diseases in the U.S. until 2050. Dr. Zobair Younossi, the Global NASH Council Chairman, presented the latest findings on the correlation between food insecurity and MAFLD in American adolescents. Additionally, Dr. Rohit Loomba shared insights into the renaming of Non-Alcoholic Fatty Liver Disease (NAFLD) and the challenges associated with it.
AASLD Voice of China丨Dr. Fengmin Lu: A1762T/G1764A Mutation Promotes HBV Replication, HNF1α Holds Promise as a Novel Therapeutic Target

AASLD Voice of China丨Dr. Fengmin Lu: A1762T/G1764A Mutation Promotes HBV Replication, HNF1α Holds Promise as a Novel Therapeutic Target

2023.12.21
From November 10th to 14th, the annual highlight of hepatology, the American Association for the Study of Liver Diseases (AASLD) 2023, was grandly held in Boston, USA. With over 200 abstracts from Chinese experts and scholars selected for oral presentations or poster sessions, the achievements were commendable. Congratulations to all! Dr. Fengmin Lu's team from Peking University has three contributions to this event (1 oral presentation and 2 posters). Today, we'll share insights from one of the posters presented on the first day, November 10th, revealing the team's academic prowess. The research discovered that the A1762T/G1764A mutation, by affecting the HBV transcriptome, can promote HBV replication (Abstract Number: 1514-C).
AASLD Voice of China | Peking University Hepatology Institute Shines with 10 Achievements at AASLD 2023

AASLD Voice of China | Peking University Hepatology Institute Shines with 10 Achievements at AASLD 2023

2023.12.21
From November 10th to 14th, the annual international event in hepatology—the American Association for the Study of Liver Diseases (AASLD) 2023—was grandly held in Boston, USA. According to incomplete statistics, more than 200 abstracts from Chinese experts and scholars were selected for oral presentations or poster exchanges at this conference, achieving fruitful results. Congratulations are extended here! The Beijing University People's Hospital and Peking University Hepatology Institute team achieved 1 oral and 9 poster presentations on scientific research in the fields of hepatic encephalopathy, fatty liver, hepatitis C, hepatitis B, and liver cancer. Some research abstracts are shared below, and "Hepatology Digest" takes you to appreciate the team's excellence.
AASLD Review | New Therapies for Hepatitis B: Vebicorvir, Selgantolimod, Bepirovirsen, Therapeutic Vaccines, and More

AASLD Review | New Therapies for Hepatitis B: Vebicorvir, Selgantolimod, Bepirovirsen, Therapeutic Vaccines, and More

2023.12.21
Currently, some patients with chronic hepatitis B (CHB) can achieve clinical cure through interferon-based antiviral treatment. To pursue clinical cure for a larger population, there is a flurry of activity in the development of new drugs. Six studies on new therapies for hepatitis B were selected for presentation at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting, to be discussed in the "Hepatitis B: New Therapies for HBV and HDV" session. Hepatology Digest has compiled this information for interested readers, and the session is scheduled for online access on November 12th at 8:30 AM local time.
AASLD Review | Emerging Therapies for Metabolism-Related Fatty Liver Disease: Ecolgnetide, Saroglitazar, Retatrutide, etc.

AASLD Review | Emerging Therapies for Metabolism-Related Fatty Liver Disease: Ecolgnetide, Saroglitazar, Retatrutide, etc.

2023.12.20
Metabolism-related fatty liver disease (MAFLD) has become the leading cause of global chronic liver disease, yet there are currently no targeted and effective treatments. In recent years, the development of new drugs for MAFLD and metabolism-related fatty liver hepatitis (MASH) has been a mix of optimism and concern. The 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting has selected six studies on novel MAFLD therapies from numerous abstract submissions. "Novel Therapeutic Approaches for MASH" will showcase relevant content, and interested readers can tune in on November 13th at 8:30 AM local time.
Dr. Chao Wu and Dr. Jie Li’s Team at Nanjing Drum Tower Hospital Focus on Non-invasive Diagnosis, Risk Factors, and Treatment Management of Hepatitis

Dr. Chao Wu and Dr. Jie Li’s Team at Nanjing Drum Tower Hospital Focus on Non-invasive Diagnosis, Risk Factors, and Treatment Management of Hepatitis

2023.12.20
Hepatitis B virus (HBV) infection is a widespread global health issue. According to the World Health Organization, as of 2019, approximately 296 million people globally suffer from chronic HBV infection, with around 1.5 million new infections annually, leading to 820,000 deaths due to HBV-related complications. Data from the Chinese Center for Disease Control and Prevention indicates that around 86 million people in China have chronic HBV infection. Simultaneously, with changes in lifestyle and dietary habits, metabolic-associated fatty liver disease (MAFLD) has become the most common chronic liver disease globally, affecting approximately one-third of the world's population. In Asia, the prevalence of MAFLD has been steadily rising, increasing from 25.28% between 1999 and 2005 to 33.90% between 2012 and 2017.
AASLD Hot Topic | Dr. Zhihong Liu of Southern Hospital: Hepatitis B Expanded Treatment, Simplified Treatment, and Progress in Functional Cure Drugs Deserve Attention

AASLD Hot Topic | Dr. Zhihong Liu of Southern Hospital: Hepatitis B Expanded Treatment, Simplified Treatment, and Progress in Functional Cure Drugs Deserve Attention

2023.12.20
The AASLD (American Association for the Study of Liver Diseases) 2023 conference was held in Boston, USA, from November 10th to 14th, marking a significant event in the field of hepatology. Hepatology Digest's reporting team was fortunate to invite Dr. Zhihong Liu from the Department of Infectious Diseases and Hepatology at Southern Hospital of Southern Medical University to share insights from the AASLD and discuss the work presented by his team at the conference, along with their learning experiences.
AASLD Interview | Professor Wai-Kay Seto’s Team: Presentation of Five Achievements in Predicting Clinical Cure of Hepatitis B and Post-operative Recurrence of Liver Cancer, and Commentary on Liver Disease Research Trends

AASLD Interview | Professor Wai-Kay Seto’s Team: Presentation of Five Achievements in Predicting Clinical Cure of Hepatitis B and Post-operative Recurrence of Liver Cancer, and Commentary on Liver Disease Research Trends

2023.12.20
The 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2023) has just concluded in Boston, USA. The team led by Professor Wai-Kay Seto from the University of Hong Kong focused on five research outcomes in the areas of mother-to-child transmission blockage and clinical cure of Hepatitis B, clearance of Hepatitis C, post-operative recurrence of liver cancer, and post-liver transplant management. These outcomes were presented at the meeting, with two of them being shared in the form of oral presentations. Professor Seto's team has been committed to the clinical management and scientific research of chronic liver diseases, achieving fruitful results. Hepatology Digest invited the team's principal researchers to interpret the findings and comment on the trends in liver disease research and share their experiences at the conference. The interview video is shared below.
Professor Lili Liu and Associate Researcher Xuejing Zou’s Team: Targeting Macrophages May Offer New Treatment Strategies for IInhibiting MASH Progres

Professor Lili Liu and Associate Researcher Xuejing Zou’s Team: Targeting Macrophages May Offer New Treatment Strategies for IInhibiting MASH Progres

2023.12.20
The AASLD 2023 Annual Meeting, hosted by the American Association for the Study of Liver Diseases, recently concluded in Boston, USA. A team led by Professor Lili Liu and Associate Researcher Xuejing Zou from Southern Medical University's Nanfang Hospital in China, including Physician Ziyong Zhang, presented their research in the field of Metabolism-Associated Steatohepatitis (MASH) during the conference's oral presentations (Oral 38). Their study suggests that targeting macrophages may offer a new strategy to inhibit the progression of MASH to liver fibrosis. Dr. Ziyong Zhang was invited to introduce their research at the conference and share his experiences and insights.
AASLD Interview | Professor Bernd Schnabl: Delving into the “Gut-Liver Axis,” Decoding the Role of Gut Microbiota in the Diagnosis and Treatment of Autoimmune Liver Diseases

AASLD Interview | Professor Bernd Schnabl: Delving into the “Gut-Liver Axis,” Decoding the Role of Gut Microbiota in the Diagnosis and Treatment of Autoimmune Liver Diseases

2023.12.14
The gut microbiome, a complex ecosystem within the human intestinal tract, has a broad impact on physiological functions. Gut microbiome imbalance has become one of the most critical environmental factors in the onset of chronic inflammatory diseases. The liver is one of the first identified targets of autoimmune attack. In recent years, with deeper research into the gut microbiome, the relationship between gut microbiota and liver diseases has gained increasing attention. Studies have found that gut microbiota might play a role in the development and progression of autoimmune liver diseases, making the treatment of gut microbiota imbalance a potential key target.